Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Liver trigger holds the key to boosting gene therapy success

Indiana University School of Medicine researchers have uncovered vital insights regarding a liver trigger that blocks an undesired immune response from gene therapy, surprisingly resulting in the activation of specific immune cells, despite the liver's typical role in suppressing immune responses.

7 Dec 2023

Refeyn launches KaritroMP for rapid and reproducible characterization of large viral vectors

Refeyn, a leader in mass photometry technology, announces the launch of its macro mass photometry platform, KaritroMP.

From Refeyn 4 Dec 2023

New insights into how SARS-CoV-2 evades our immune system

This review in Cellular and Molecular Immunology delves into the innate immune response to SARS-CoV-2, exploring how the virus evades immunity and the potential role of innate immunity in long-COVID and vaccine responses, shedding light on future therapeutic strategies.

23 Nov 2023

CEPI and University of Oxford launch new project to initiate vaccine development against Junín virus

The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly hemorrhagic fevers with epidemic and pandemic potential.

6 Nov 2023

CRISPR gene editing study provides insights into how autism gene affects brain development

Researchers have used CRISPR gene editing, stem cells and human neurons to study the impact of a gene that is commonly mutated in autism.

5 Oct 2023

Maternal COVID-19 shots significantly lowered infant hospitalizations during Omicron wave

Study found that maternal COVID-19 vaccination during pregnancy significantly reduces the risk of COVID-19-related hospitalizations in infants under six months, particularly boosting protection during the first three months of life. With 78% of the hospitalized infants born to unvaccinated mothers, the research emphasizes the crucial role of maternal vaccination in safeguarding infants too young for vaccination.

2 Oct 2023

Study suggests antibodies triggered by COVID-19 mRNA vaccination may depend on prior infection history

Researchers evaluated distinct immune responses to mRNA and vector-based COVID-19 vaccines and natural SARS-CoV-2 infections.

17 Aug 2023

Adenovirus infection linked to rare blood clotting disorder

Platelets, or thrombocytes, are specialized cellular fragments that form blood clots when we get scrapes and traumatic injuries. Viral infections, autoimmune disease, and other conditions can cause platelet levels to drop throughout the body, termed thrombocytopenia.

10 Aug 2023

Is COVID-19 vaccination linked to psoriasis emergence or flare-ups?

Researchers explored the relationship between COVID-19 vaccination and psoriasis onset or exacerbation.

7 Aug 2023

Intranasally administered SARS-CoV-2 RBD-based nanoparticle vaccine provides protection against lung pathology and viral load

In a recent study, researchers working at Ohio State University in the United States of America (USA) developed an intranasal subunit vaccine.

2 Aug 2023

Penn Medicine researchers identify new therapeutic target for Alzheimer's disease

A gene encoding a protein linked to tau production-;tripartite motif protein 11 (TRIM11)-;was found to suppress deterioration in small animal models of neurodegenerative diseases similar to Alzheimer's disease (AD), while improving cognitive and motor abilities, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

27 Jul 2023

Gene Therapy Contract Development and Manufacturing: Challenges and Future Perspectives

In this interview conducted at the Cell and Gene Therapy Summit Tour London, we speak to Ramin Baghirzade, Global Head of Commercial at Charles River for Gene Therapy, about the Gene Therapy CDMO solutions that Charles River Laboratories offers and more.

From Charles Rivers Laboratories Cell and Gene Therapy 18 Jul 2023

Novel approach: intranasal vaccination strategy targets Omicron COVID-19 variants

Researchers tested the efficacy of a two to three-dose intranasal (IN) regimen of the NDV-HXP-S vaccine.

14 Jul 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Cell and gene therapy CDMO Andelyn Biosciences celebrates over 20 years of leadership and innovation with opening of new 180,000 square foot manufacturing headquarters

Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, today formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center (ACC), located in the Innovation District in Columbus, Ohio.

From Andelyn Biosciences 23 Jun 2023

Catalent expands OneBio® suite for integrated development, manufacturing and supply across biologic modalities

Catalen today announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.

From Catalent 16 Jun 2023

Researchers review the principles of universal vaccine development for key pandemic potential viruses

A recent review addressed the efforts to develop universal vaccines for viruses at family and genus levels.

16 Jun 2023

Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.

From Charles Rivers Laboratories Cell and Gene Therapy 13 Jun 2023

Experimental decoy provides long-term protection from SARS-Cov-2 infection

An experimental "decoy" provided long-term protection from infection by the pandemic virus in mice, a new study finds.

30 May 2023

Nemours Children's Health selected to conduct first gene therapy clinical trial for Morquio A syndrome

As part of the Foundation for the National Institutes of Health Accelerating Medicines Partnership Bespoke Gene Therapy Consortium, Nemours Children's Health has been chosen to conduct a first-of-its-kind gene therapy clinical trial for Morquio A syndrome.

16 May 2023